Headline
The latest stories from AHA Today.
The Senate Appropriations Committee’s Subcommittee on Labor, Health and Human Services, Education and Related Agencies today held a hearing to review the U.S. response to the Ebola outbreak in the Democratic Republic of the Congo and other emerging health threats.
Legislative proposals for a Medicare public option could negatively affect patient access to care and significantly reduce payments to hospitals, AHA Executive Vice President Tom Nickels said during a panel discussion today at America’s Health Insurance Plans’ National Health Policy Conference in…
The Centers for Medicare & Medicaid Services today released new state tools and guidance that provide standard monitoring metrics and recommended research methods for Section 1115 demonstrations that test innovative approaches to Medicaid eligibility and coverage policies.
The Centers for Medicare & Medicaid Services today updated its Medicare and Medicaid drug spending dashboards with 2017 data.
The House Energy and Commerce Health Subcommittee today held a hearing to discuss seven bills aimed at increasing competition in the prescription drug market to lower prices.
Prior authorization still poses significant challenges to physicians and patients, according to a new survey by the American Medical Association. The survey looks at progress by health plans to implement reforms outlined in a 2018 consensus statement by six organizations, including the AHA and…
The American Board of Medical Specialties Board of Directors yesterday announced its plan to implement recommendations to improve the continuing certification process.
Creating a government-run, Medicare-like option on the individual health insurance exchanges could negatively affect patient access to care and reduce hospital payments by nearly $800 billion over 10 years.
The House Energy and Commerce Health Subcommittee today held a hearing on the president’s fiscal year 2020 budget request for the Department of Health and Human Services.
A federal court has ordered a Texas-based company to stop producing compounded drug products intended to be sterile until the company complies with the Federal Food, Drug, and Cosmetic Act and other requirements.